Blog

Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders

Aug 20 • 3 min read

Vancouver, Canada – Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (‘Clearmind’ or the ‘company’), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the submission of a patent application under the international Patent Cooperation Treaty (‘PCT’) as part of the company’s ongoing collaboration with the with Yissum Research…

MindBio Reports Promising Phase 2A Results for Depression Treatment with LSD

Aug 19 • 4 min read

MindBio Therapeutics Corp. (CSE) has recently unveiled promising durability data from its Phase 2A clinical trials, which tested MB22001, the company’s innovative self-administered, take-home microdose of Lysergic Acid Diethylamide (LSD), as a treatment for depression. This development underscores MindBio’s commitment to advancing psychedelic medicine as a viable option for mental health treatment. Positive Outcomes in…

Psychedelic News Roundup: August 16th, 2024

Aug 16 • 8 min read

A lot has happened the past week. Let us summarize some of the events surrounding psychedelic drug development companies and the industry as a whole. Lykos Therapeutics Cuts 75% of Staff Lykos Therapeutics announced a reorganization plan following the FDA’s rejection of its application for an MDMA-based drug intended to treat PTSD. Despite the setback,…

Who is the Ketamine Queen?

Aug 16 • 3 min read

Jasveen Sangha, a name that has recently made headlines, is now facing serious legal consequences following the tragic death of actor Matthew Perry. Known in some circles as the “Ketamine Queen,” Sangha has been indicted for her alleged role in Perry’s overdose, a development that has shocked both fans and those aware of her activities…

After Last Week’s FDA Decision, Everyone’s Talking About What’s Next

Aug 16 • 5 min read

After last week’s rejection of MDMA, everyone has been conjecturing about the future of psychedelics as medicine. Questions surrounding all the delays and need for more capital have taken hold of mainstream media. Throughout all of this, one of the most interesting conversations we’ve heard recently is Vivek Ramaswamy’s interview with Balaji Srinivasan. While Psychedelic…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548549550551552553554555556